How UK Medical Cannabis Clinics Changed After November 2018

Since November 2018, the landscape of medical cannabis in the UK has undergone significant transformation. The official rescheduling of cannabis-based products for medicinal use by the UK government unlocked new possibilities. Patients gained legal access, while clinics had to adapt swiftly to evolving regulations and professional standards.

This blog post dives into key changes affecting UK medical cannabis clinics with a focus on regulation and oversight, unlicensed medicine risk disclosure, prescribing authority, and specialist competence. We'll also highlight sector growth, differences in provider quality, and patient choice challenges, supported by frameworks like the Care Quality Commission (CQC) and the General Medical Council (GMC) Specialist Register.

Background: What Changed in November 2018?

Before November 2018, prescribing cannabis-based medicines was practically impossible in the UK, as cannabis was classified alongside the most strictly controlled drugs. The rescheduling moved cannabis-based products for medicinal use (CBPMs) into Schedule 2 of the Misuse of Drugs Regulations – allowing specialist doctors to prescribe legally.

This change immediately affected medical cannabis clinics offering consultations and prescriptions. It introduced a legal framework but also created fresh challenges around quality assurance, transparency, and patient safety.

1. Regulation and Clinic Oversight

Care Quality Commission (CQC) and Medical Cannabis Clinics

Medical cannabis clinics providing consultations and prescription services are healthcare providers and therefore come under the scope of the CQC, England’s independent regulator for health and social care services.

Registration: Clinics must register with the CQC to operate lawfully. This ensures a baseline standard for governance, patient safety, and clinical care.
Inspections and Ratings: Clinics are routinely inspected and rated based on quality domains such as safety, effectiveness, and leadership.
Transparency: CQC publishes inspection reports and ratings online, helping patients distinguish reputable providers.

Since 2018, there has been a steady increase in CQC-registered medical cannabis clinics reflecting sector growth. However, the market remains fragmented, and the quality ratings reveal notable differences between providers.

Differences Between Providers

Not all clinics meet the same standards or levels of care. Some clinics:

Have experienced medical teams on the GMC Specialist Register;
Follow established protocols for patient evaluation and monitoring;
Provide thorough risk disclosure relating to unlicensed medicines.

Others may offer faster appointments but lack transparency about their prescribing clinicians or clinical governance procedures—a concern borne out in some CQC inspection reports. This gap highlights why regulation and ongoing oversight are essential.

2. Unlicensed Medicines and Risk Disclosure

The medical cannabis products prescribed under UK law are mostly unlicensed medicines. This means they have not undergone the same rigorous clinical trials as fully licensed drugs.

Risks and Responsibilities

Prescribers have a legal and ethical obligation to:

Inform patients about the unlicensed status of cannabis-based medicines;
Discuss potential side effects, uncertainties, and benefits;
Obtain informed consent before initiating treatment.

This risk disclosure is a key safety pillar and is monitored by the CQC during inspections.

Challenges for Patients

Patients often find inconsistent information about:

Which conditions cannabis medicine is appropriate for;
Potential risks versus benefits;
Costs involved, including medicine and dispensing fees hidden in subscription bundles.

Clinics with robust patient education and transparency have an edge in quality rankings, but there remains variability across the sector.

3. Who is Legally Allowed to Prescribe Medical Cannabis?

Prescribing Authority Rules

The key legal change in November 2018 was that only doctors on the GMC Specialist Register can prescribe CBPMs. This includes:

Consultants documented with a clinical specialty;
General practitioners (GPs) only if they have specialist registration, which is rare;
Doctors with appropriate knowledge and experience relating to the clinical condition.

This ruling excludes many doctors from prescribing on first appointment without additional qualifications, reinforcing the importance of specialist competence and scope.

Why Specialist Competence Matters

Patients should ask clinics for:

Registration number of their prescribing doctor—a common "vague answer" red flag if withheld;
Evidence the prescriber is on the GMC Specialist Register in the relevant specialty;
Details on the prescriber's experience with CBPMs.

Clinics that do not disclose these details may be less compliant or cutting corners—potentially jeopardizing patient safety and care quality.

4. Specialist Competence and Scope of Practice

Helpful site

Following legal guidance, competent prescribing for medical cannabis requires:

A working knowledge of the latest evidence about CBPMs;
Understanding of alternative treatments and when cannabis is appropriate;
Ability to monitor and manage side effects and clinical outcomes;
Good communication skills to discuss risks and benefits.

Specialists typically come from neurology, pain medicine, palliative care, or psychiatry. Clinics claiming "specialist doctors" but unwilling to name them or show credentials should be approached with caution.

Sector Growth and Patient Choice Challenges

Rapid Expansion of Providers

The UK medical cannabis sector has grown quickly since 2018, with private clinics emerging nationwide. This saturation offers choice but also creates confusion as:

There is significant variation in clinical standards and transparency;
Some clinics bundle consultations with expensive subscription plans hiding medicine costs;
Many patients struggle to verify claims about efficacy and qualifications.

Without careful oversight, patients risk engaging with providers offering inconsistent care.

Making Informed Patient Choices

To navigate this complex market, patients should:

Seek clinics registered with the CQC;
Confirm the prescribing doctor's GMC Specialist Register details and registration number;
Ask specifically about the unlicensed status of medicines and how risks are communicated;
Compare clinic inspection reports where available;
Beware of claims that cannabis cures or helps "everything"—such statements are not supported by current evidence;
Understand all costs upfront, including medicine, dispensing, and consultation fees.

Summary Table: Key Changes in UK Medical Cannabis Clinics After 2018

Aspect Before November 2018 After November 2018 Legal Prescribing Not permitted for cannabis medicines Allowed only by GMC Specialist Register doctors Clinic Regulation Minimal oversight specific to cannabis CQC registration and inspections mandatory Medicines Status Illegal to prescribe cannabis-based products Mostly unlicensed medicines with mandated risk disclosure Patient Information Limited awareness; mostly illegal access Risk disclosure required; variable quality of info Provider Quality N/A Wide variation; inspection reports available Sector Growth Non-existent Rapid expansion; increasing patient demand

Final Thoughts

The UK's shift in policy in November 2018 opened the door to legal medical cannabis prescriptions, triggering major changes. While the regulatory frameworks of the CQC and GMC have raised standards, patient safety and quality vary widely across clinics.

Patients need to be vigilant: always ask for the prescribing doctor's registration number, verify their specialist status, understand the unlicensed nature of prescribed cannabis medicines, and scrutinize total costs before committing. Clinics that hide information or make blanket claims should be avoided.

In this growing market, transparency and competence are the cornerstones of safe and effective care.